U.S. Markets closed

Evotec AG (EVT.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
15.47+0.05 (+0.32%)
At close: 5:35PM CEST

Evotec AG

Manfred Eigen Campus
Essener Bogen 7
Hamburg 22419
Germany
49 40 5 60 81 0
http://www.evotec.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees1,316

Key Executives

NameTitlePayExercisedAge
Dr. Werner Lanthaler MBA, MPAChief Exec. Officer and Member of Management Board792kN/A49
Mr. Enno SpillnerChief Financial Officer and Member of Management Board158kN/A47
Dr. Mario Polywka Ph.D.Chief Operating Officer and Member of Management Board614kN/A54
Dr. Cord Dohrmann Ph.D.Chief Scientific Officer and Member of Management Board501kN/A53
Katja SchraderChief EditorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of immunology and inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, Respiratory, and Immunology and Inflammation; EVT770 for diabetes type 2/1; and EVT801, EVT701, and EVT601 for oncology. The company has alliances and partnerships with AstraZeneca AB; Bayer Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; CHDI Foundation, Inc.; MedImmune; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Innovation; Novartis AG; Sanofi; ex scientia Ltd; Bayer AG; Pfizer; C4X Discovery Holdings plc; Asahi Kasei Pharma Corporation; and STORM Therapeutics, as well as a research collaboration with Inserm Transfert SA. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec AG’s ISS Governance QualityScore as of August 1, 2017 is 4. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.